Beigene Mahogany

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Rituximab or Obinutuzumab Versus Lenalidomide plus Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL). The MAHOGANY trial
Description: This trial assesses the effectiveness of Zanubrutinib Plus Rituximab or Obinutuzumab combination v's Lenalidomide plus Rituximab combination in patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Study Phase: Phase 3
Principal Investigator: Prof Elisabeth Vandenberghe
Further information

Olympia 3

A Phase 3, Open label, Randomized Study Comparing the Safety and Efficacy of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
Description: This trial is for patients who have Diffuse Large B-cell Lymphoma and have not yet received any treatment for it. Patients will be assigned to 1 of 2 treatment arms- arm A combines a new drug, Odronextamab, with CHOP chemotherapy and arm B is CHOP chemotherapy plus Rituximab.
Study Phase: Phase 3
Principal Investigator: Dr Rob Henderson
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.